CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bio Medica Laboratories Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bio Medica Laboratories Ltd
Plot-254, Sector-F Sanwer Road
Phone: +91 7314102751p:+91 7314102751 INDORE, 452015  India Ticker: BMLLBMLL
Business Summary
Bio Medica Laboratories Ltd is engaged in the manufacturing of pharmaceutical parenteral formulations. The Company manufactures variety of products, comprising ethical drugs, generic drugs and over the-counter drugs (OTC) in the form of injectables namely Liquid injections and dry powder injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a range of medical needs and preferences both domestically as well as exported through merchant exporter. It offers a total of 58 products. Its products include 100 ml Amikacin Sulphate IP Injection, Vitamin B12, D3 & Calcium Gluconolactobionate Injection, 2ml Amikacin Sulphate Injection, Buprenorphine Injection, and 30 ml Amikacin Sulphate Injection. Buprenorphine injection is used as a short-term treatment to relieve severe pain in people who need an opioid pain medication and who cannot be treated with other pain medications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20253/31/2025-----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer SantoshKale 10/28/2024 10/28/2024
Company Secretary, Compliance Officer PratikshaBhandari 4/3/2026 4/3/2026
Managing Director, Executive Director PradeepMehta 39 10/28/2024 8/14/2015
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 12,575,001 (As of 5/29/2026)
Stock Exchange: NSE


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, June 2, 2026